

[Midazolam](#)

Statut de médicament essentiel

Section:

[5. Medicines for neurological disorders 5.1. Medicines for central nervous system disorders 5.1.1. Antiseizure medicines](#)

Codes ATC: [N05CD08](#)

EMLc

Indication

Status epilepticus Code ICD11: [8A66](#)

INN

Midazolam

Type de médicament

Chemical agent

Type de liste

Liste de base

Additional notes

Midazolam injection may be used for buccal administration when solution for oromucosal administration is not available.

Formulations

Parenteral > General injections > unspecified: 1 mg per mL in 5 mL vial (for buccal administration) ; 5 mg per mL in 1 mL vial (for buccal administration) ; 5 mg per mL in 3 mL vial (for buccal administration)

Local > Buccal > Solution: 5 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration) ; 5 mg per mL in 1 mL pre-filled syringe (for oromucosal administration) ; 5 mg per mL in 1.5 mL pre-filled syringe (for oromucosal administration) ; 5 mg per mL in 2 mL pre-filled syringe (for oromucosal administration) ; 10 mg per mL in 0.25 mL pre-filled syringe (for oromucosal administration) ; 10 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration) ; 10 mg per mL in 0.75 mL pre-filled syringe ; 10 mg per mL in 1 mL pre-filled syringe (for oromucosal administration)

Historique des statuts LME

Ajouté pour la première fois en 2015 ([TRS 994](#))

Modifié en 2023 ([TRS 1049](#))

Sexe

Tous

Âge

Aussi recommandé pour les enfants

Équivalence thérapeutique

La recommandation concerne ce médicament spécifique

Renseignements sur le brevet

Patents have expired in most jurisdictions

Lire la suite [sur les brevets](#).

Wikipédia

[Midazolam](#)

DrugBank

[Midazolam](#)

Résumé des preuves et recommandation du comité d'experts

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended amendments to the listing for midazolam for status epilepticus on the EML and EMLc to better describe the available dosage forms.